Clinical Trial Search

Primary: Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28) — 1; 1; 0 Participants

Primary: Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period) — -0.56; 0.07 Percent — p=<0.0001

Primary: Change of Total Neuropathy Score — -6.8; 0.2 units on a scale

Primary: Self-reported Pain From Baseline to 1, 3, and 6 Months Post-intervention — 50.24; 47.42; 45.42; 43.57 units on a scale — p=0.791

Primary: Percentage of Participants With Any Significant Comorbidities — 42.7 percentage of participants

Primary: Number of Subjects Reporting European Medical Agency (EMA) Defined Adverse Events of Interest (AEIs) (Any) & Onset Dates of AEIs Using a Card Based-adverse Drug Reaction…

Primary: Glycemic Control (HbA1c) — 8.8; 9; 8.5 percentage of glycated hemoglobin

Primary: Number of Participants With Untoward Events — 0 Participants

Primary: Measuring the Accuracy of Commercial Heart Rate Monitors. — .91; .84; .91; .83 Correlation Coefficient

Primary: Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP) — 157.873; 158.236; 158.594; -22.483 mm Hg — p=0.184

Primary: Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Small Dense Low Density Lipoprotein (sdLDL) Fraction — -6.50; 5.05; -12.35; 4.64 Percent…

Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs) — 3; 3; 14; 3 Participants

Primary: The Percentage of Patients With at Least 75% Reduction in Psoriasis Area and Severity Index (PASI 75) Response at Week 16 — 68.2; 70.4 Percentage (%)

Primary: Change in HbA1c (Glycosylated Haemoglobin) — -1.16; -1.30 Percentage of HbA1c — p=0.0435

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 — -55.65; -68.25; -74.00; -5.91 percent change — p=<0.001